Moleele, SSGravestock, DRousseau, ALVan Zyl, RL2009-04-202009-04-202008-09Moleele, SS, Gravestock, D, Rousseau, AL and Van Zyl, RL. 2008. Pyrimidines in antimalarial drug designSACI-GDCh Bi-National Organic Chemistry Conference 2008. Incorporating the 10th Frank Warren Conference, Kruger National Park, South Africa, 14-19 September 2008, pp 1http://hdl.handle.net/10204/3321SACI-GDCh Bi-National Organic Chemistry Conference '08 Incorporating the 10th Frank Warren Conference, Kruger National Park, South Africa, 14-19 September 2008Malaria causes the death of 2-3 million people annually, most of these children under 5 years of age. Approximately 300 million cases of acute malaria are reported each year, 90% of these in Africa. Until recently, folate metabolism has been successfully targeted in both prophylaxis and treatment of malaria. Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) is a well defined and validated target for malaria chemotherapy. Unfortunately, resistance to the most commonly used anti-DHFR drugs, including pyrimethamine 1 now limits the clinical usefulness of these drugsenAntimalarial drugsPyrimidinesMalariaPlasmodium falciparum dihydrofolate reductase-thymidylate synthasePfDHFR-TSMalaria chemotherapyAnti-DHFR drugsSACI-GDCh Bi-National Organic Chemistry Conference 2008Conference PresentationMoleele, S., Gravestock, D., Rousseau, A., & Van Zyl, R. (2008). Pyrimidines in antimalarial drug design. SACI-GDCh Bi-National Organic Chemistry Conference 2008. http://hdl.handle.net/10204/3321Moleele, SS, D Gravestock, AL Rousseau, and RL Van Zyl. "Pyrimidines in antimalarial drug design." (2008): http://hdl.handle.net/10204/3321Moleele S, Gravestock D, Rousseau A, Van Zyl R, Pyrimidines in antimalarial drug design; SACI-GDCh Bi-National Organic Chemistry Conference 2008; 2008. http://hdl.handle.net/10204/3321 .TY - Conference Presentation AU - Moleele, SS AU - Gravestock, D AU - Rousseau, AL AU - Van Zyl, RL AB - Malaria causes the death of 2-3 million people annually, most of these children under 5 years of age. Approximately 300 million cases of acute malaria are reported each year, 90% of these in Africa. Until recently, folate metabolism has been successfully targeted in both prophylaxis and treatment of malaria. Plasmodium falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS) is a well defined and validated target for malaria chemotherapy. Unfortunately, resistance to the most commonly used anti-DHFR drugs, including pyrimethamine 1 now limits the clinical usefulness of these drugs DA - 2008-09 DB - ResearchSpace DP - CSIR KW - Antimalarial drugs KW - Pyrimidines KW - Malaria KW - Plasmodium falciparum dihydrofolate reductase-thymidylate synthase KW - PfDHFR-TS KW - Malaria chemotherapy KW - Anti-DHFR drugs KW - SACI-GDCh Bi-National Organic Chemistry Conference 2008 LK - https://researchspace.csir.co.za PY - 2008 T1 - Pyrimidines in antimalarial drug design TI - Pyrimidines in antimalarial drug design UR - http://hdl.handle.net/10204/3321 ER -